CaaS Capital Management is investing across all regions, industries, and capital structures.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
CaaS Capital Management is investing across all regions, industries, and capital structures. CaaS feels strongly in providing liquidity — Capital as a Service — to our partners and pursues this objective with great vigor and energy. CaaS uses a unique combination of fundamental and quantitative inputs when making investment decisions.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
8/2021 | T-knife | Series B | 110M |
3/2021 | Amunix | Series B | 117M |
1/2021 | Werewolf Therapeutics | Series B | 0 |
7/2021 | Artios Pharma | Series C | 0 |
9/2022 | Ventyx Biosciences | Post-IPO Equity | 0 |
3/2021 | StrideBio | Series B | 0 |
4/2021 | Arcellx | Series C | - |
3/2022 | 2seventy bio | Post-IPO Equity | 0 |
6/2021 | Umoja Biopharma | Series B | 0 |
2/2021 | Cyteir Therapeutics | Series C | 0 |
9/2022 | Solid Biosciences | Post-IPO Equity | 75M |
11/2021 | HotSpot Therapeutics | Series C | 0 |
7/2021 | Turnstone Biologics | Series D | 0 |
3/2021 | Rapid Micro Biosystems | Private Equity Round | 0 |
3/2022 | 2seventy bio | Post-IPO Equity | 0 |
11/2021 | HotSpot Therapeutics | Series C | 0 |
8/2021 | T-knife | Series B | 0 |
7/2021 | Artios Pharma | Series C | 0 |
7/2021 | Turnstone Biologics | Series D | 0 |
6/2021 | Umoja Biopharma | Series B | 0 |
4/2021 | Arcellx | Series C | - |
3/2021 | Rapid Micro Biosystems | Private Equity Round | 0 |
3/2021 | StrideBio | Series B | 0 |
3/2021 | Amunix | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|